Quantitative profiling of oxylipins in plasma and atherosclerotic plaques of hypercholesterolemic rabbits.
Oxylipins are oxidation products of polyunsaturated fatty acids (PUFAs) that affect a broad range of physiological processes, including cell proliferation, inflammation, inflammation resolution, and vascular function. Moreover, oxylipins are readily detectable in plasma, and certain subsets of oxylipins have been detected in human atherosclerotic lesions. Taken together, we set out to produce a detailed quantitative assessment of plasma and plaque oxylipins in a widely used model of atherosclerosis, to identify potential biomarkers of disease progression. We administered regular chow or regular chow supplemented with 0.5% cholesterol (HC) to male New Zealand white rabbits for 12 weeks to induce hypercholesterolemia and atherosclerosis. Our targeted lipidomic analyses of oxylipins on plaques isolated from rabbits fed the HC diet detected 34 oxylipins, 28 of which were in compliance with our previously established quality control acceptance criteria. The arachidonic acid (AA) metabolite derived from the COX pathway, 6-keto-PGF1α was the most abundant plaque oxylipin, followed by the linoleic acid (LA) metabolites 9-HODE, 13-HODE and 9,12,13-TriHOME and the arachidonic acid (AA)-derivatives 11-HETE and 12-HETE. We additionally found that the most abundant oxylipins in plasma were three of the five most abundant oxylipins in plaque, namely 11-HETE, 13-HODE, and 9-HODE. The studies reported here make the first step towards a comprehensive characterization of oxylipins as potentially translatable biomarkers of atherosclerosis.
Merck and Co., Inc, Merck Research Laboratories, Kenilworth, NJ, 07033, USA. lazar.bojic@merck.com.
Lazar A
LA
Bojic
Merck and Co., Inc, Merck Research Laboratories, Kenilworth, NJ, 07033, USA.
David G
DG
McLaren
Leiden Amsterdam Centre for Drug Research, Netherlands Metabolomics Centre, 2300 LA, Leiden, The Netherlands.
Amy C
AC
Harms
Leiden Amsterdam Centre for Drug Research, Netherlands Metabolomics Centre, 2300 LA, Leiden, The Netherlands.
Thomas
T
Hankemeier
Leiden Amsterdam Centre for Drug Research, Netherlands Metabolomics Centre, 2300 LA, Leiden, The Netherlands.
Adrie
A
Dane
Merck and Co., Inc, Merck Research Laboratories, Kenilworth, NJ, 07033, USA.
Sheng-Ping
SP
Wang
Merck and Co., Inc, Merck Research Laboratories, Kenilworth, NJ, 07033, USA.
Ray
R
Rosa
Merck and Co., Inc, Merck Research Laboratories, Kenilworth, NJ, 07033, USA.
Stephen F
SF
Previs
Merck and Co., Inc, Merck Research Laboratories, Kenilworth, NJ, 07033, USA.
Douglas G
DG
Johns
Merck and Co., Inc, Merck Research Laboratories, Kenilworth, NJ, 07033, USA.
Jose M
JM
Castro-Perez
D000818:Animals; D002851:Chromatography, High Pressure Liquid; D005231:Fatty Acids, Unsaturated / Q000378:metabolism; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood* / Q000378:metabolism; D008297:Male; D013058:Mass Spectrometry; D054883:Oxylipins / Q000097:blood* / Q000378:metabolism; D058226:Plaque, Atherosclerotic / Q000097:blood* / Q000378:metabolism; D011817:Rabbits
D005231:Fatty Acids, Unsaturated; D054883:Oxylipins
Atherosclerosis; Cholesterol; Eicosanoids; Lipids; Mass spectrometry; Plaque